Observations from Carrie Ambler, CSO, LightOx.
Attending BioAsia in Hyderabad this year was a chance to step back and see the bigger picture: how fast the global life sciences landscape is moving, and how India is carving its place in it. Having worked in the country over the last decade, I’ve seen steady growth but this year, it felt different. There’s momentum, yes, but there’s also acceleration: in capability, in ambition, and in global relevance.
Here are five takeaways I’m bringing back.
- Growth isn’t just steady anymore, it’s speeding up
India’s track record in generics, vaccines, and manufacturing is well known. But the pace of expansion beyond that foundation is what caught my eye this year. More companies are developing drugs in-house biologics, small molecules, novel APIs and building pipelines that go beyond replication.
What this means for life sciences
Innovation isn’t confined to traditional hubs anymore. As more ecosystems start producing meaningful early-stage science, the field becomes both more exciting and more competitive. There are new opportunities to partner, access talent, and explore pipelines but the bar is higher, and differentiation matters more than ever.
- BioAsia is stepping onto the global stage
The conference itself reflects India’s rising influence. Global pharma companies, in-licensing teams, and decision-makers were all present, making it feel comparable to top-tier international events. At the same time, there was a grounded focus on local health needs from obesity and diabetes to chronic wounds.
What this means for life sciences
Engagement across diverse ecosystems is no longer optional. Conferences like BioAsia are becoming strategic venues for partnerships and visibility. Companies that show up where innovation is happening and who build relationships across markets will find themselves ahead of the curve.
- Moving beyond biosimilars is gaining traction
India has long excelled at biosimilars and producing high-quality, accessible medicines. What’s shifting now is the attention on originality: new APIs, differentiated therapeutics, and patent-protected pipelines. Companies are thinking about long-term value, not just replication.
What this means for life sciences
The sector is evolving from following established formulas to competing on uniqueness and IP strength. Success will increasingly hinge on building pipelines that are globally competitive and stand out from the crowd.
- New modalities are being explored but with a realistic lens
Traditional drug formats still dominate, yet there’s a clear openness to alternative therapeutic approaches and delivery mechanisms. Importantly, companies aren’t pursuing novelty for novelty’s sake they’re balancing creativity with regulatory and clinical realities.
What this means for life sciences
Innovation is only as valuable as its ability to be translated into real-world therapies. Success requires thinking beyond the lab: scalable, credible, and compliant approaches are what will turn early ideas into treatments that reach patients.
- Partnerships start and stay with people
One message came through repeatedly: relationships matter. In India, building trust, understanding culture, and sharing purpose are as important as commercial alignment. The human element isn’t optional, it’s central.
What this means for life sciences
Even in an increasingly global, digital world, in-person engagement remains critical. Companies that invest time in authentic relationships will be the ones that forge lasting, impactful collaborations.
Final thought: India is a market and a mindset you can’t ignore
With over 1.4 billion people, a rapidly maturing regulatory framework, and growing innovation capabilities, India represents both a strategic partner and a commercial opportunity. For LightOx, the takeaway is clear: understanding the ecosystem, engaging thoughtfully, and building the right partnerships will be key to moving our science forward.
In life sciences, speed and scale matter but so do insight and connection. The companies that combine all three are the ones that will benefit most.
